Robert Flavell, MD, PhD, is the Chief of Molecular Imaging and Therapeutics Clinical Section in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. He received his medical degree from Weill Cornell Medical College, and his PhD from the Rockefeller University as part of the Tri-Institutional MD PhD program. He completed his one-year internship at the Memorial Sloan­Kettering Cancer Center in New York. Dr. Flavell completed his radiology residency at UCSF, including an NIH T32 funded research fellowship, and subsequently completed a one-year fellowship in nuclear medicine. In June 2016. he joined the faculty as an Assistant Professor in Residence, and since 2019 he has served as the chief of Molecular Imaging and Therapeutics in the Department of Radiology and Biomedical Imaging.

Dr. Flavell’s laboratory focuses on the development of new molecular imaging and therapeutic tools in cancer, with a particular focus on prostate cancer and hematologic malignancies. Major areas of focus include the development of novel theranostic and radiopharmaceutical therapy methods, as well as methods for imaging the tumor microenvironment.

Expertise:
Nuclear Medicine, Molecular Imaging, Theranostics.

Specialty:
Novel radiotracer development, oncologic imaging, PET imaging, hyperpolarized 13C magnetic resonance imaging

Professional Interests:
Radiology, molecular imaging, PET imaging, prostate cancer, nuclear medicine, radiochemistry, hyperpolarized 13C magnetic resonance imaging

Education and Training:
• Medical School: Weill Cornell Medical College, New York
• PhD: The Rockefeller University, New York
• Internship: Memorial Sloan­-Kettering Cancer Center, New York
• Residency: University of California, San Francisco
• Fellowship: University of California, San Francisco – Nuclear Medicine